Skip to main content
. 2005 Aug 15;146(5):670–678. doi: 10.1038/sj.bjp.0706371

Figure 5.

Figure 5

Role for the tissue and plasma kallikreins in PAR4-mediated oedema formation in the mouse paw. Effect of FE999024 (tissue kallikrein inhibitor, 60 μmol kg−1) or FE999026 (plasma kallikrein inhibitor, 60 μmol kg−1) on the oedema formation (a) and granulocyte recruitment (b) observed following PAR4 activation with AYPGKF-NH2 (50 μg). Values are mean±s.e.m. of n=8 per group. *Significantly different from the vehicle+AYPGKF-NH2 group, P<0.05.